Literature DB >> 7628115

Multivariate receiver-operating characteristic curve analysis: prostate cancer screening as an example.

E K Shultz1.   

Abstract

The evolution of test performance analysis should include the long-term costs and benefits associated with testing. Evolutionary laboratory techniques to achieve this include introduction of a new methodological technique, a multivariate extension to a current analytical technique, receiver-operating characteristic (ROC) curve analysis (MultiROC analysis). This extension to ROC methodology allows the comparison of composite test rules in a format similar to that of ROC curves. Statistical properties, guidelines for use, and a detailed example are described. MultiROC is used in the outcomes analysis of the value of screening for prostate cancer. The effect of age and different test decision thresholds are examined in an extension of a previously published outcomes analysis. The results indicate that the variations in test performances caused by these components are important in assigning a final cost:benefit ratio of screening for prostate cancer.

Entities:  

Mesh:

Year:  1995        PMID: 7628115

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

1.  A head to head evaluation of 8 biochemical scanning tools for unmeasured ions.

Authors:  Thomas J Morgan; Chris M Anstey; Matthew B Wolf
Journal:  J Clin Monit Comput       Date:  2016-04-12       Impact factor: 2.502

2.  Tumor SUVmax Normalized to Liver Uptake on (18)F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Authors:  Jihyun Park; Kyoung Jin Chang; Young Seok Seo; Byung Hyun Byun; Joon Ho Choi; Hansol Moon; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2014-08-01

3.  Validity of carbohydrate deficient transferrin and other markers as diagnostic aids in the detection of alcohol related seizures.

Authors:  G Bråthen; K S Bjerve; E Brodtkorb; G Bovim
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

4.  HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants.

Authors:  Jamie L Felton; David Cuthbertson; Megan Warnock; Kuldeep Lohano; Farah Meah; John M Wentworth; Jay Sosenko; Carmella Evans-Molina
Journal:  Diabetologia       Date:  2021-10-12       Impact factor: 10.460

5.  The receiver operational characteristic for binary classification with multiple indices and its application to the neuroimaging study of Alzheimer's disease.

Authors:  Xia Wu; Juan Li; Napatkamon Ayutyanont; Hillary Protas; William Jagust; Adam Fleisher; Eric Reiman; Li Yao; Kewei Chen
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2013 Jan-Feb       Impact factor: 3.710

Review 6.  Mass Spectrometry Imaging: A Review of Emerging Advancements and Future Insights.

Authors:  Amanda Rae Buchberger; Kellen DeLaney; Jillian Johnson; Lingjun Li
Journal:  Anal Chem       Date:  2017-12-13       Impact factor: 6.986

7.  Changes in the Chemical Barrier Composition of Tears in Alzheimer's Disease Reveal Potential Tear Diagnostic Biomarkers.

Authors:  Gergő Kalló; Miklós Emri; Zsófia Varga; Bernadett Ujhelyi; József Tőzsér; Adrienne Csutak; Éva Csősz
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

8.  Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22.

Authors:  John D Kelly; Tim J Dudderidge; Alex Wollenschlaeger; Odu Okoturo; Keith Burling; Fiona Tulloch; Ian Halsall; Teresa Prevost; Andrew Toby Prevost; Joana C Vasconcelos; Wendy Robson; Hing Y Leung; Nikhil Vasdev; Robert S Pickard; Gareth H Williams; Kai Stoeber
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240

9.  MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.

Authors:  Benjamin C Calhoun; Bryce Portier; Zhen Wang; Eugen C Minca; G Thomas Budd; Christopher Lanigan; Raymond R Tubbs; Larry E Morrison
Journal:  BMC Cancer       Date:  2016-08-30       Impact factor: 4.430

10.  DTI measures identify mild and moderate TBI cases among patients with complex health problems: A receiver operating characteristic analysis of U.S. veterans.

Authors:  Keith L Main; Salil Soman; Franco Pestilli; Ansgar Furst; Art Noda; Beatriz Hernandez; Jennifer Kong; Jauhtai Cheng; Jennifer K Fairchild; Joy Taylor; Jerome Yesavage; J Wesson Ashford; Helena Kraemer; Maheen M Adamson
Journal:  Neuroimage Clin       Date:  2017-06-24       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.